Watch Dr. Singer’s TV interview: Lemtrada’s FDA decision

Feb 11 2014

On Feb 7,  Barry Singer, MD and a person living with MS that participated in a Lemtrada trial were interviewed regarding the impact of the FDA denial of Lemtrada (alemtuzumab).  The treatment demonstrated a reduction of new attacks by 49-55% compared to Rebif in two clinical trials.  Dr. Singer addresses why the FDA made their decision, but talks about the appeal process for trying to reverse the decision.  Lemtrada has recently been approved for use in Europe, Canada and Australia.  Learn how to join a petition to the FDA to get Lemtrada approved for use in the United States.



BY: Barry Singer, MD DATE: February 11, 2014 TOPIC: MS Center News